Patents Examined by James Rogers
  • Patent number: 10233235
    Abstract: Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: March 19, 2019
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Joshua M. Thurman, V. Michael Holers
  • Patent number: 10072050
    Abstract: The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: September 11, 2018
    Assignee: EMD Millipore Corporation
    Inventors: Nanying Bian, Neil Soice, Shari Spector, Kara Levine
  • Patent number: 10052376
    Abstract: The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: August 21, 2018
    Assignee: ALTERNATIVE INNOVATIVE TECHNOLOGIES LLC
    Inventors: Sergey B. Onikienko, Alexander V. Zemlyanoi, Boris A. Margulis, Irina V. Guzhova, Anna A. Pimenova
  • Patent number: 10023608
    Abstract: Disclosed are methods of purifying a protein sample. More specifically, provide are methods of removing or reducing the amount of high molecular weight species and/or high mannose species from a protein sample using a mixed mode chromatography step and a hydrophobic interaction chromatography step.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 17, 2018
    Assignee: AMGEN INC.
    Inventors: Junfen Ma, Xiaoyang Zhao, Brian Williamson
  • Patent number: 9968369
    Abstract: One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: May 15, 2018
    Assignee: Genzyme Corporation
    Inventors: W. Scott McDougal, Dianne E. Sacco, Alexander Schwarz, Jean-Marie Vogel
  • Patent number: 9957318
    Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: May 1, 2018
    Assignee: ABBVIE INC.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Christopher Chumsae
  • Patent number: 9957319
    Abstract: Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: May 1, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno
  • Patent number: 9938337
    Abstract: The present invention relates to methods for harvesting of antibodies from an antibody library. The antibodies are harvested by utilizing a certain epitope that is analogous to the epitope of the antigen used for immunization but that may differ in global physical and biochemical properties allowing the production of antibodies against antigens that normally cannot be utilized as immunizing agents. The present invention furthermore relate to fields of use for harvested antigens in industry, agriculture and healthcare.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: April 10, 2018
    Assignee: Carviar ApS
    Inventor: Janus Beierholm Larsen
  • Patent number: 9920112
    Abstract: The present invention relates to modified immunoglobulin-binding proteins, e.g., Staphylococcus protein A, having improved binding specificity for immunoglobulins and methods of making and using the same.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: March 20, 2018
    Assignee: EMD Millipore Corporation
    Inventor: Shari Spector
  • Patent number: 9895452
    Abstract: The present invention relates to hydrogels comprising 1,2-diol or 1,3-diol groups acetalized with a radiopaque species of one or more covalently bound radiopaque halogens which are imageable during embolization therapy. The invention further relates to methods of making radiopaque polymers and radiopaque hydrogel microspheres to provide an imageable drug delivery system.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: February 20, 2018
    Assignee: BIOCOMPATIBLES UK LIMITED
    Inventors: Stéphane Hohn, Andrew Lennard Lewis
  • Patent number: 9890205
    Abstract: A method of purifying a sample containing a desired protein includes the steps of (i) providing a packed chromatographic column having positively charged porous particles, (ii) equilibrating the column to the conditions to which the desired protein in the sample is to elute, (iii) contacting the sample with the packed chromatographic column such that the sample volume applied to the packed chromatographic column is less than or equal to the interparticle space of the positively charged porous particles within the packed chromatographic column, (iv) eluting the desired protein from the packed chromatographic column, where the desired protein is in a purer state and in the conditions to which the packed chromatographic column was equilibrated; where the desired protein is an antibody, an antibody fragment, an antibody derivative, or an antibody fusion protein.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: February 13, 2018
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Peter Gagnon
  • Patent number: 9890377
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: February 13, 2018
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Patent number: 9878066
    Abstract: One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: January 30, 2018
    Assignee: HYPERBRANCH MEDICAL TECHNOLOGY, INC.
    Inventors: Kenneth E. Stockman, Michael A. Carnahan, Keith R. D'Alessio, Mark W. Grinstaff
  • Patent number: 9868948
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: January 16, 2018
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Patent number: 9855338
    Abstract: Various biodegradable polyglutamate-amino acids comprising recurring units of the general formulae (I) and (II) are prepared. Such polymers are useful for variety of drug, biomolecule and imaging agent delivery applications.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 2, 2018
    Assignee: Nitto Denko Corporation
    Inventors: Lei Yu, Gang Zhao, Sang Van, Sanjib Kumar Das, Zhongling Feng, Xiaoli Fu, Xinghe Wang, Yi Jin, Fu Chen
  • Patent number: 9849198
    Abstract: Encompassed are embodiments of activatable nanoprobes useful for in vivo longitudinal imaging of drug hepatotoxicity with oxidative and nitrosative stress as the safety biomarkers. Both H2O2 and ONOO? are important mediators of radical stress. Two channels of optical detection, intrinsically free from cross-talk, were engineered into superconducting polymer nanoparticles to generate chemiluminescence resonance energy transfer between the conjugated polymer matrix of the nanoparticle and an incorporated chemiluminescent substrate allowing for the luminescent detection of H2O2 and fluorescence resonance energy transfer between the polymer matrix and an oxidation-degradable fluorophore for ratiometric detection of ONOO These nanoprobes have been applied for real-time in vivo monitoring of hepatotoxicity resulting from challenges from drugs.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 26, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jianghong Rao, Kanyi Pu, Adam Shuhendler
  • Patent number: 9850315
    Abstract: The present disclosure relates to a method for the purification of a human IgG-CH1 domain comprising molecule using an antigen-binding protein that is capable of binding to an epitope that is comprised in the CH1 domain of each of human IgG1, human IgG2, human IgG3 and human IgG4. The disclosure further relates to the antigen-binding proteins that can be used in the method of the disclosure. The frame-work regions of the antigen-binding proteins of the invention preferably correspond to those of antibodies that naturally are devoid of light chains as may e.g. be found in camelids. The disclosure further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, and to the uses of such immunoadsorbent materials for the purification of IgG-CH1 domain containing molecules from a variety of species.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: December 26, 2017
    Assignee: BAC IP B.V.
    Inventors: Wilhelmus Josephus Johanna Hermans, Sven Blokland, Maria Anna van Kesteren, Johanna Magaretha Horrevoets, Franciscus Johan Marinus Detmers
  • Patent number: 9845338
    Abstract: A method of purifying an antibody composition comprises application of anion exchange chromatography late in the purification process. An ultrafiltration/diafiltration-purified antibody composition is subjected to anion exchange chromatography (AEX) to form a pharmaceutically-pure antibody composition.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: December 19, 2017
    Assignee: Synthon Biopharmaceuticals BV
    Inventors: Bastiaan Pieter Arjan Kokke, Everdina Josephina Wilhelmina Wijk-Basten Van, Thomas Antonius Bernardus Beijer De, Maria Marzá Pérez, Michel Hendrikus Maria Eppink
  • Patent number: 9828418
    Abstract: The invention relates to a process for enriching IgA (and IgM) from IgA-comprising material. In particular, it relates to a sequential elution process of an anion exchanger that leads to an advantageous enrichment and separation of monomeric and dimeric IgA.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: November 28, 2017
    Assignee: CSL BEHRING AG
    Inventors: Ibrahim El Menyawi, Marius Loetscher, Doreen Siegemund
  • Patent number: 9821078
    Abstract: Provided is a polymeric micelle pharmaceutical preparation that can increase the ratio of contrast at tumor site to background contrast in a short period of time after administration of a lactosome and can suppress the ABC phenomenon so that the lactosome can be administered more than once within a short span. A branched-type amphiphilic block polymer comprising: a multi-branched hydrophilic block comprising sarcosine; and a hydrophobic block comprising polylactic acid. The branched-type amphiphilic block polymer, wherein the number of branches of the hydrophilic block is 3. A molecular assembly comprising the branched-type amphiphilic block polymer. The molecular assembly further comprising a linear type amphiphilic block polymer.
    Type: Grant
    Filed: February 27, 2016
    Date of Patent: November 21, 2017
    Assignees: SHIMADZU CORPORATION, KYOTO UNIVERSITY
    Inventors: Eiichi Ozeki, Shunsaku Kimura, Akira Makino